PTPN11 and neoplasm: In conclusion, these results underline a mechanistic rationale for combining RAS(ON) G12C-selective inhibitors, such as RMC-4998, with a second targeted compound, such as the SHP2 inhibitor RMC-4550, that in addition to enhancing the tumour cell intrinsic responses can directly target the TME and potentiate immune responses.